Free Trial
OTCMKTS:BICX

Biocorrx Q2 2025 Earnings Results & Report

Biocorrx logo
$0.21 0.00 (0.00%)
As of 11/13/2026 10:26 AM Eastern

Biocorrx reported Q2 2025 earnings on August 14, 2025. The company reported EPS of -$0.07, while revenue was $180 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
During Market Hours

Biocorrx EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Biocorrx Revenue Results

Actual Revenue
$180 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Biocorrx's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Biocorrx Q2 2025 Earnings FAQ

Biocorrx (OTCMKTS:BICX) reported earnings of -$0.07 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

Biocorrx reported revenue of $180 thousand for Q2 2025.

Biocorrx's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biocorrx on the company's earnings history page.

Biocorrx Earnings Headlines

Biocorrx (BICX) Projected to Release Quarterly Earnings on Tuesday
BioCorRx Inc
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.tc pixel
BioCorRx Inc.
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), Inc. is a healthcare company focused on substance-use-disorder treatment and related products. Its BioCorRx Recovery Program is an outpatient approach that combines medication-assisted treatment with counseling and ongoing support for people seeking treatment for alcohol or opioid dependence.

The company has also pursued pharmaceutical products intended to support addiction treatment, including long-acting formulations. Its business includes developing treatment offerings and working to make them available through healthcare providers.

BioCorRx has also offered UnCraveRx, a medically supervised weight-management program. Its activities are centered on treatment and support services rather than traditional pharmaceutical manufacturing or general medical care.

View Biocorrx Profile